Assessment of preoperative magnetic resonance imaging staging in patients with hepatocellular carcinoma undergoing resection compared with the seventh american joint committee on cancer system

Investigative Radiology

Volumn 47, Issue 11, 2012, Pages 634-641

  An, Chansik ^a   Choi, Gi Hong ^b   Lee, Hye Sun ^c   Kim, Myeong Jin ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Departments of Surgery   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

hepatocellular carcinoma; magnetic resonance imaging; prognosis; radiologic staging system; survival

Indexed keywords

ADULT; AGED; AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEM; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER RESECTION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY;

EID: 84867261802     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182630e8d     Document Type: Article

References (33)

1. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
2. Vauthey J, Dixon E, Abdalla EK, et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB. 2010;12:289-299.
3. Libbrecht L, Bielen D, Verslype C, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl. 2002;8:749-761.
4. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38:1034-1042.
5. Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective anal-Sis of the UNOS/OPTN database. Liver Transpl. 2006;12:1504-1511.
6. Hanna RF, Kased N, Kwan SW, et al. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol. 2008;190:47-57.
7. Nishie A, Yoshimitsu K, Asayama Y, et al. Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma. AJR Am J Roentgenol. 2008;190:81-87.
8. Shirabe K, Kajiyama K, Abe T, et al. Predictors of microscopic portal vein invasion by hepatocellular carcinoma: measurement of portal perfusion defect area ratio. J Gastroenterol Hepatol. 2009;24:1431-1436.
9. Ariizumi S, Kitagawa K, Kotera Y, et al. A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOB-DTPA)Yenhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2011;18:575-585.
10. Roayaie S, Blume IN, Thung SN, et al. A s-Stem of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850-855.
11. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409-1417.
12. McGraw OK, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30-46.
13. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic s-Stem (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology. 2001;34: 529-534.
14. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-723.
15. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61:92-105.
16. Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM s-Stems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-922.
17. Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799-805.
18. Kikuchi LO, Paranagu-Vezozzo DC, Chagas AL, et al. Nodules less than 20mm and vascular invasion are predictors of survival in small hepatocellular carcinoma. J Clin Gastroenterol. 2009;43:191-195.
19. Nathan H, Mentha G, Marques HP, et al. Comparative performances of staging s-Stems for early hepatocellular carcinoma. HPB (Oxford). 2009;11:382-390.
20. Guglielmi A, Ruzzenente A, Pachera S, et al. Comparison of seven staging s-Stems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597-604.
21. Cho YK, Chung JW, Kim JK, et al. Comparison of 7 staging s-Stems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008;112:352-361.
22. Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging s-Stem for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer. 2010;116:3006-3014.
23. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging s-Stems in an American cohort. Hepatology. 2005; 41:707-716.
24. Nanashima A, Sumida Y, Abo T, et al. Modified Japan Integrated Staging is currently the best available staging s-Stem for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol. 2006;41:250-256.
25. Chung H, Kudo M, Takahashi S, et al. Comparison of three current staging s-Stems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445-452.
26. Rhee H, Kim MJ, Park MS, et al. Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acidYenhanced MRI [pubished online ahead of print 2012]. Br J Radiol.
27. Park MS, Kim S, Patel J, et al. Hepatocellular carcinoma: detection with diffusion-weighted vs. contrast-enhanced MRI in pre-transplant patients [pubished online ahead of print 2012]. Hepatology.
28. Morana G, Grazioli L, Kirchin MA, et al. Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol. 2011;46:225-239.
29. Motosugi U, Ichikawa T, Sano K, et al. Double-dose gadoxetic acidYenhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol. 2011;46:141-145.
30. Le-Moigne F, Durieux M, Bancel B, et al. Impact of diffusion-weighted MR imaging on the characterization of small hepatocellular carcinoma in the cirrhotic liver. Magn Reson Imaging. 2012;30:656-665.
31. Chang JM, Lee JM, Lee MW, et al. Superparamagnetic iron oxideYenhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Invest Radiol. 2006;41:168-174.
32. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T. Invest Radiol. 2011;46:383-389.
33. von Falkenhausen M, Lutterbey G, Morakkabati Spitz N, et al. High-fieldstrength MR imaging of the liver at 3.0 T: intraindividual comparative study with MR imaging at 1.5 T. Radiology. 2006;241:156-166.